MD Pharmaceutical Supply, LLC

CLOSEOUT LETTER MD Pharmaceutical Supply, LLC MARCS-CMS 637815 — April 13, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: Via Email Reference #: FEI 3012369470 Product: Drugs Recipient: Recipient Name Mr. Richard J. Romeo Recipient Title President and Owner MD Pharmaceutical Supply, LLC P.O. Box 244 Hanover , PA 17331 United States rromeo@mdpharmaceutical.com Issuing Office: Division of Pharmaceutical Quality Operations I United States Secondary Issuing Offices United States Dear Mr. Romeo: The Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our Warning Letter (Case # 637815) dated November 22, 2022. Based on our evaluation, it appears that you have addressed the deviations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections. This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The FDA expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should deviations be observed during a subsequent inspection or through other means. Sincerely, /S/ Christina Alemu-Cruickshank Compliance Officer Division of Drug Quality I Content current as of: 04/17/2026 Regulated Product(s) Drugs